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to-LM angle.
Catheter-induced spasm must be considered in the diagnosis of
LMCA disease. However, interventional cardiologists are appro-
priately concerned about prolonging catheterization and perform-
ing additional procedures for suspected significant LMCA lesions,
given the high risks involved. Given these risks, some cardiologists’
routinely place intra-aortic balloons pumps and begin intravenous
heparin and nitroglycerin with suspected LMCA lesions. A
eading text on invasive cardiology describes significant LMCA
tenosis as a very high-risk situation and suggests a “hit and
un” technique of brief engagements with minimal contrast
njections to get enough information to proceed, yet not
eopardize patients’ safety (4). Given these reasons, the assess-
ent of LMCA stenosis remains challenging. Attempts to
meliorate possible spasm by using intracoronary nitroglycerin
eems like a reasonable routine in hemodynamically stable
atients with significant LM stenosis.
Another concern in referring these patients for CABG is
cclusion of important bypass grafts from competitive flow from
atent native LMCA, as shown in previous studies (5). In our
study, 33.3% patients had occluded internal mammary conduits
to the left anterior descending artery, likely from similar
physiology.
There were several limitations to this study. This was a
retrospective study based on chart review; we were dependent on
the catheterization report for assessment of LMCA stenosis.
There were other possibilities, besides spasm, as to how a lesion
that might be present on first, angiogram might be absent on a
subsequent angiogram; these include overcall of the pre-CABG
angiogram, an undercall of the post-CABG angiogram, develop-
ment of diffuse atherosclerosis when the original lesion was focal,
possible alteration of flow patterns that might have been altered
by the presence of grafts and differing vasomotor tone, and
angulations between the 2 studies. In addition, only a minority
of the patients who had CABG for LMCA disease had a repeat
coronary angiography at our facility; thus, we might have either
underestimated or overestimated the incidence of patients who
underwent CABG for LMCA spasm during this time. None-
theless, our findings, confirmed in 1 patient to be spasm with
IVUS and strongly suggested in the others, when added to
previous observations, suggest that LM spasm is a finite but
underdiagnosed entity, at times resulting in inappropriate
bypass surgery.
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Letter to the Editor
Lack of Activation of the
Antihypertensive Cardiac
Hormones ANP and BNP in
Human Hypertension
Macheret and colleagues (1) examined the association between
different processing variants of circulating atrial (ANP) and B-type
(BNP) natriuretic peptides and stages of hypertension in a
population-based cohort. A significant decrease in BNP/N-
terminal proBNP/N-terminal proANP was observed in partici-
pants with prehypertension; no difference was observed in hyper-
tensive participants compared with normotensive participants, and
no differences were observed for proBNP/proANP levels across all
categories of blood pressure. The authors concluded that there is a
relative deficiency of natriuretic peptides in early hypertension that
might be a target for therapeutic interventions.
A general limitation of cross-sectional analysis is that observed
associations might be the sum of overlying effects; this seems
particularly problematic with natriuretic peptides, which are in-
volved in several physiological feedback loops that are only partly
understood (2). Although the authors used multivariable modeling
(1), there might be residual confounding resulting from the strong
association of natriuretic peptide levels with metabolic traits such
as diabetes mellitus (3) and reverse causality resulting from the
activation of natriuretic peptides in myocardial hypertrophy and
coronary heart disease (4,5), both of which conditions were
associated with categories of blood pressure and the latter of which
was not adjusted for in multivariable analysis.
Macheret et al. (1) stated that “there is no definitive way to
correct for medication usage.” When acknowledging this, it is
questionable why participants with antihypertensive medication
were not excluded from the primary analysis, which would have been
the “cleanest” way to deal with this problem. Indeed, the effect of
distinct antihypertensive drugs on natriuretic peptide levels is un-
clear and different drug classes might have opposite effects on
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number of antihypertensive drugs. Accordingly, inhibitors of the
renin-angiotensin system have been shown to decrease BNP levels
(6), whereas beta-blockers increased BNP levels (7) in patients
with heart failure. When excluding participants taking antihyper-
tensive medication in the study by Macheret et al. (1), there was no
significant difference for any of the natriuretic peptides between
normotensive and prehypertensive participants in the multivariable
analysis.
There is a body of evidence showing that ANP and BNP
decrease blood pressure (2,8) and hence the conclusion of Mach-
eret et al. (1) might be plausible. However, although natriuretic
peptides are involved in the regulation of blood pressure, this does
not conversely mean that elevated blood pressure per se stimulates
secretion of natriuretic peptides. There is no evidence supporting
this assumption, which is the key justification for the authors’
conclusion. Given these limitations, the conclusion regarding a
“relative deficiency” in early hypertension seems rather speculative.
When analyzing the results more conservatively, there was no
significant difference in natriuretic peptide levels across categories
of blood pressure except for an increase in BNP levels in stage 2
hypertension, and it remains questionable whether this finding was
solely due to blood pressure effects. Results would be consistent
with earlier reports showing that mechanical strain is the key
stimulus for secretion of natriuretic peptides (9) and that natri-
uretic peptides might be relevant for blood pressure regulation only
in advanced stages of hypertensive heart disease (4).
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